Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.
Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of 4L Gastrointestinal Stromal Tumor
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.
La FDA aprobó QINLOCKTM (ripretinib) para el tratamiento de adultos con tumor avanzado del estroma gastrointestinal (GIST) que han recibido 3 o más tratamientos previos para su GIST.
Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST.
In this issue of LRG Science, the relationship between overall survival (OS) and access to treatments after imatinib failure is explored. In 2019, the LRG published this research in Clinical Sarcoma Research and this issue includes commentary from experts. LRG Science endeavors to be a respected source of timely, science-based information built on real world data designed for those whose focus is to increase patient survival from GIST and other cancers.
During this webcast presentation, Dr. Michael Heinrich will discuss these two new treatment options for advanced GIST. Dr. Heinrich will explain how each of these drugs works to target mutations for which there has previously been no targeted treatment and discuss the current coronavirus outbreak.
Drug repository programs have the potential to be a key component in accessing life-saving treatments. In a landscape where prices for cancer drugs are escalating, many face a challenge in obtaining life-saving treatments. There are many resources for overcoming these obstacles, but it is clearly not enough for those already struggling with the challenges of a cancer diagnosis.
Senior Scientific Director Pete Knox reports on current and emerging GIST treatments and the mutations they address. New research in GIST is happening, and there may be even more therapies around the corner.
Deciphera Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for ripretinib for Priority Review. Ripretinib is an investigational broad-spectrum KIT and PDGFRa inhibitor for the treatment of patients with gastrointestinal stromal tumors (GIST).
In a new article from the NCI concerning the January 2020 approval of Ayvakit, (produced by Blueprint Medicines) the Life Raft Group is acknowledged in the section, “Capturing the Patient Experience.” We are proud to have played a role in supporting the research involved in bringing a new treatment to market for GIST patients.